Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02041429 · ClinicalTrials.gov registry record · Phase 1
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02041429 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT02041429, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I/II research study is evaluating a combination of drugs called paclitaxel and ruxolitinib as a possible treatment for inflammatory breast cancer. Ruxolitinib is a newly discovered drug that has been shown to block a pathway (called the IL6/JAK/Stat pathway) that may be important in cancer, including breast cancer. Blocking this pathway may stop cancer cells from growing. Ruxolitinib has been approved by the FDA for patients with bone marrow disease, and this is the first study using this drug in combination with paclitaxel for breast cancer. Paclitaxel (also called Taxol) is an FDA drug approved for breast cancer patients. Paclitaxel works by blocking the small microtubules inside cancer cells and preventing cell growth. Information from laboratory experiments suggests that ruxolitinib might also have effects on breast cancer.These studies have shown that ruxolitinib may make paclitaxel more effective.
Interventions
- DRUG Paclitaxel
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-02 |
| Est. Completion | 2021-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02041429
The ClinicalTrials.gov registry entry for NCT02041429 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT02041429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02041429 about?
NCT02041429 is a clinical study titled "Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca". This phase I/II research study is evaluating a combination of drugs called paclitaxel and ruxolitinib as a possible treatment for inflammatory breast cancer. Ruxolitinib is a newly discovered drug that has been shown to block a pathway (called the IL6/JAK/Stat pathway) that may be important in cance...
What is the current status of trial NCT02041429?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-02. Estimated completion is 2021-01.
What interventions are being tested in trial NCT02041429?
The interventions under investigation include: Paclitaxel (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02041429?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.